Matches in SemOpenAlex for { <https://semopenalex.org/work/W2214851279> ?p ?o ?g. }
- W2214851279 endingPage "e0140574" @default.
- W2214851279 startingPage "e0140574" @default.
- W2214851279 abstract "Background Nevirapine extended-release (NVP-XR) taken once daily remains an effective antiretroviral agent for patients infected with HIV-1 strains that do not harbor resistance mutations. Presence of tablet remnants of NVP XR in stools was reported in 1.19% and 3.05% of subjects in two clinical trials. However, the prevalence may have been underestimated because the information was retrospectively collected in the studies. Methods Between April and December 2014, we prospectively inquired about the frequency of noticing tablet remnants of NVP XR in stools in HIV-1-infected patients who switched to antiretroviral regimens containing NVP XR plus 2 nucleos(t)ide reverse-transcriptase inhibitors. Patients were invited to participate in therapeutic drug monitoring of plasma concentrations of NVP 12 or 24 hours after taking the previous dose (C12 and C24, respectively) of NVP XR using high-performance liquid chromatography. The information on clinical characteristics, including plasma HIV RNA load and CD4 lymphocyte count, at baseline and during follow-up was recorded. Results During the 9-month study period, 272 patients switched to NVP XR-based regimens and 60 (22.1%) noticed tablet remnants of NVP XR in stools, in whom 54.2% reported noticing the tablet remnants at least once weekly. Compared with patients who did not notice tablet remnants, those who noticed tablet remnants had a higher mean CD4 lymphocyte count (629 vs 495 cells/mm3, P = 0.0002) and a similar mean plasma HIV RNA load (1.57 vs 1.61 log10 copies/mL, P = 0.76) on switch. At about 12 and 24 weeks after switch, patients who noticed tablet remnants continued to have a similar mean plasma HIV RNA load (1.39 vs 1.43 log10 copies/mL, P = 0.43; and 1.30 vs 1.37 log10 copies/mL, P = 0.26, respectively), but had a lower median NVP C12 (3640 vs 4730 ng/mL, P = 0.06), and a similar median NVP C24 (3220 vs 3330 ng/ml, P = 0.95) when compared with those who did not notice tablet remnants. Conclusions The presence of tablet remnants of NVP XR in stools is not uncommon in HIV-1-infected Taiwanese patients receiving NVP XR-based antiretroviral regimens, which does not have an adverse impact on the virological and immunological outcomes." @default.
- W2214851279 created "2016-06-24" @default.
- W2214851279 creator A5005236574 @default.
- W2214851279 creator A5005558061 @default.
- W2214851279 creator A5010605516 @default.
- W2214851279 creator A5011769937 @default.
- W2214851279 creator A5014258071 @default.
- W2214851279 creator A5019097914 @default.
- W2214851279 creator A5020276376 @default.
- W2214851279 creator A5025368461 @default.
- W2214851279 creator A5037812360 @default.
- W2214851279 creator A5039004671 @default.
- W2214851279 creator A5047717026 @default.
- W2214851279 creator A5049507002 @default.
- W2214851279 creator A5051501183 @default.
- W2214851279 creator A5054435118 @default.
- W2214851279 creator A5054470933 @default.
- W2214851279 creator A5064613277 @default.
- W2214851279 creator A5073029812 @default.
- W2214851279 creator A5078113145 @default.
- W2214851279 date "2015-10-14" @default.
- W2214851279 modified "2023-10-18" @default.
- W2214851279 title "Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study" @default.
- W2214851279 cites W1507462311 @default.
- W2214851279 cites W1543134049 @default.
- W2214851279 cites W174487234 @default.
- W2214851279 cites W178626500 @default.
- W2214851279 cites W1977008620 @default.
- W2214851279 cites W1977123905 @default.
- W2214851279 cites W1981712752 @default.
- W2214851279 cites W2028231662 @default.
- W2214851279 cites W2037649732 @default.
- W2214851279 cites W2041190841 @default.
- W2214851279 cites W2069526121 @default.
- W2214851279 cites W2121739949 @default.
- W2214851279 cites W2124431973 @default.
- W2214851279 cites W2135892517 @default.
- W2214851279 cites W2141776019 @default.
- W2214851279 cites W2406362442 @default.
- W2214851279 doi "https://doi.org/10.1371/journal.pone.0140574" @default.
- W2214851279 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4605833" @default.
- W2214851279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26465325" @default.
- W2214851279 hasPublicationYear "2015" @default.
- W2214851279 type Work @default.
- W2214851279 sameAs 2214851279 @default.
- W2214851279 citedByCount "2" @default.
- W2214851279 countsByYear W22148512792017 @default.
- W2214851279 crossrefType "journal-article" @default.
- W2214851279 hasAuthorship W2214851279A5005236574 @default.
- W2214851279 hasAuthorship W2214851279A5005558061 @default.
- W2214851279 hasAuthorship W2214851279A5010605516 @default.
- W2214851279 hasAuthorship W2214851279A5011769937 @default.
- W2214851279 hasAuthorship W2214851279A5014258071 @default.
- W2214851279 hasAuthorship W2214851279A5019097914 @default.
- W2214851279 hasAuthorship W2214851279A5020276376 @default.
- W2214851279 hasAuthorship W2214851279A5025368461 @default.
- W2214851279 hasAuthorship W2214851279A5037812360 @default.
- W2214851279 hasAuthorship W2214851279A5039004671 @default.
- W2214851279 hasAuthorship W2214851279A5047717026 @default.
- W2214851279 hasAuthorship W2214851279A5049507002 @default.
- W2214851279 hasAuthorship W2214851279A5051501183 @default.
- W2214851279 hasAuthorship W2214851279A5054435118 @default.
- W2214851279 hasAuthorship W2214851279A5054470933 @default.
- W2214851279 hasAuthorship W2214851279A5064613277 @default.
- W2214851279 hasAuthorship W2214851279A5073029812 @default.
- W2214851279 hasAuthorship W2214851279A5078113145 @default.
- W2214851279 hasBestOaLocation W22148512791 @default.
- W2214851279 hasConcept C126322002 @default.
- W2214851279 hasConcept C142462285 @default.
- W2214851279 hasConcept C159047783 @default.
- W2214851279 hasConcept C188816634 @default.
- W2214851279 hasConcept C2779130552 @default.
- W2214851279 hasConcept C2993143319 @default.
- W2214851279 hasConcept C3013748606 @default.
- W2214851279 hasConcept C71924100 @default.
- W2214851279 hasConcept C90924648 @default.
- W2214851279 hasConceptScore W2214851279C126322002 @default.
- W2214851279 hasConceptScore W2214851279C142462285 @default.
- W2214851279 hasConceptScore W2214851279C159047783 @default.
- W2214851279 hasConceptScore W2214851279C188816634 @default.
- W2214851279 hasConceptScore W2214851279C2779130552 @default.
- W2214851279 hasConceptScore W2214851279C2993143319 @default.
- W2214851279 hasConceptScore W2214851279C3013748606 @default.
- W2214851279 hasConceptScore W2214851279C71924100 @default.
- W2214851279 hasConceptScore W2214851279C90924648 @default.
- W2214851279 hasIssue "10" @default.
- W2214851279 hasLocation W22148512791 @default.
- W2214851279 hasLocation W22148512792 @default.
- W2214851279 hasLocation W22148512793 @default.
- W2214851279 hasLocation W22148512794 @default.
- W2214851279 hasLocation W22148512795 @default.
- W2214851279 hasOpenAccess W2214851279 @default.
- W2214851279 hasPrimaryLocation W22148512791 @default.
- W2214851279 hasRelatedWork W2048864317 @default.
- W2214851279 hasRelatedWork W2105776266 @default.
- W2214851279 hasRelatedWork W2140384375 @default.
- W2214851279 hasRelatedWork W2603130550 @default.
- W2214851279 hasRelatedWork W4206018297 @default.